Historically, gene therapy in AD focused on targeted intracerebral delivery of neurotrophic factors such as nerve growth factor (NGF) [52] or brain-derived neurotrophic factor (BDNF) [53], based on the observation that basal forebrain cholinergic neurons are particularly vulnerable to degeneration in early AD. This evidence concerns the gene BDNF and Alzheimer disease.